Suchen und filtern

Gefundene Studien

RAMOS-Study A randomized, multicenter open label phase II trial of Paclitaxel + Ramucirumab versus Paclitaxel alone in patients with squamous-cell carcinoma of the esophagus, refractory or intolerant to combination therapy with Fluoropyrimidine and Platinum-based drugs AIO-STO-0216/ass · Rekrutierung beendet Studie anzeigen

DANTE-Trial (Phase ll) A randomized, open-label Phase II efficacy and safety study of Atezolizumab in combination with FLOT versus FLOT alone in patients with gastric cancer and adenocarcinoma of the oesophago-gastric junction (MO30039) AIO-STO-0317 · Rekrutierung beendet Studie anzeigen

RAMSES – FLOT7 Perioperative RAMucirumab in combination with FLOT versus FLOT alone for reSEctable eSophagogastric adenocarcinoma - A phase II/III trial of the AIO AIO-STO-0315/ass · Rekrutierung beendet Studie anzeigen

CaboCHECK Cabozantinib in adult patients with advanced renal cell carcinoma following prior systemic check point inhibition therapy: a retrospective, non-interventional study AIO-NZK-0118/ass · Rekrutierung beendet Studie anzeigen

AIO-NET-0113 A Phase 3, Randomized, Placebo-controlled, Parallel-group, Multicenter, Double-blind Study to Evaluate the Efficacy and Safety of Telotristat Etiprate (LX1606) in Patients with Carcinoid Syndrome (CS) Refractory to Somatostatin Analog (SSA) Therapy AIO-NET-0113 · Rekrutierung beendet Studie anzeigen

SPINET-Tria A Phase 3, prospective, randomized, double-blind, multi-center study of the efficacy and safety of lanreotide Autogel/Depot 120 mg plus BSC vs. placebo plus BSC for tumour control in subjects with well differentiated, metastatic and/or unresectable, typical or atypical, lung neuroendocrine tumours. AIO-NET-0116/ass · Rekrutierung beendet Studie anzeigen

SEQTOR-Study Randomized open label study to compare the efficacy and safety of everolimus followed by chemotherapy with STZ-5FU upon progression or the reverse sequence, chemotherapy with STZ-5FU followed by everolimus upon progression, in advanced progressive pNETs AIO-NET-0215/ass · Rekrutierung beendet Studie anzeigen

CLARINET FORTE-Trial Efficacy and safety of lanreotide Autogel® 120 mg administered every 14 days in well differentiated, metastatic or locally advanced, unresectable pancreatic or midgut neuroendocrine tumours having progressed radiologically while previously treated with lanreotide Autogel® 120 mg administered every 28 days. AIO-NET-0216/ass · Rekrutierung beendet Studie anzeigen

DURTRERAD 2 ARM RANDOMIZED PHASE II TRIAL TO ASSESS THE FEASIBILITY AND EFFICACY OF A TREATMENT WITH DURVALUMAB (MEDI4736) A PDL1-INHIBITOR PLUS TREMELIMUMAB A CTLA-4- INHIBITOR IN COMBINATION WITH RADIOTHERAPY AND A TREATMENT WITH DURVALUMAB IN COMBINATION WITH RADIOTHERAPY AS FIRST-LINE THERAPY FOR PATIENTS WITH NON-RESECTABLE LOCALLY ADVANCED HPV NEGATIVE HNSCC – A COMPARISON WITH A HISTORICAL CONTROL GROUP-

AIO-KHT-0120/ass · Studie beendet Studie anzeigen

PanaMa Randomized phase II study for evaluation of efficacy and safety of maintenance treatment with 5-FU/FA plus panitumumab vs. 5-FU/FA alone after prior induction treatment with mFOLFOX6 plus panitumumab and re-induction with mFOLFOX6 plus panitumumab in case of progression for first-line treatment of patients with metastatic colorectal cancer AIO-KRK-0212 · Rekrutierung beendet Studie anzeigen